Bayer Schering Pharma AG, Germany, has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.

Bayer Schering Pharma AG, Germany, has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.

H. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 3,849 million growing 15% in constant exchange rates compared to the first quarter results of 2009. Profit from operations was DKK 1,254 million, an increase of 32% compared to the same period last year.

Boehringer Ingelheim and Micromet, Inc. (Nasdaq: MITI) have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

Bayer Schering Pharma AG, Germany, has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA).

Merck & Co., Inc. (NYSE: MRK) announced financial results for the first quarter of 2010. Worldwide sales for the first quarter of 2010 were $11.4 billion. Net income for the first quarter was $299 million. Foreign exchange for the quarter favorably affected global sales performance by 4 percent.

AstraZeneca and POZEN Inc. announced the US Food and Drug Administration (FDA) has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.